On March 28, 2023,
B. Riley Securities
initiated coverage of Gritstone Oncology with
a Buy recommendation.
Analyst Price Forecast Suggests 259.88% Upside
As of March 29, 2023,
the average one-year price target for Gritstone Oncology is $8.92.
The forecasts range from a low of $2.02 to a high of $21.00.
The average price target represents an increase of 259.88% from its latest reported closing price of $2.48.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Gritstone Oncology
is $15MM, a decrease of 22.81%.
The projected annual non-GAAP EPS
is -$1.43.
What are Large Shareholders Doing?
Point72 Asset Management
holds 7,680K shares
representing 8.76% ownership of the company.
In it’s prior filing, the firm reported owning 0K shares, representing
an increase
of 100.00%.
Redmile Group
holds 6,931K shares
representing 7.91% ownership of the company.
In it’s prior filing, the firm reported owning 6,953K shares, representing
a decrease
of 0.31%.
The firm
increased
its portfolio allocation in GRTS by 41.13% over the last quarter.
Frazier Life Sciences Management
holds 5,162K shares
representing 5.89% ownership of the company.
In it’s prior filing, the firm reported owning 5,237K shares, representing
a decrease
of 1.45%.
The firm
decreased
its portfolio allocation in GRTS by 99.89% over the last quarter.
Versant Venture Management
holds 3,561K shares
representing 4.06% ownership of the company.
No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 2,168K shares
representing 2.47% ownership of the company.
No change in the last quarter.
What is the Fund Sentiment?
There are 160 funds or institutions reporting positions in Gritstone Oncology.
This is a decrease
of
7
owner(s) or 4.19% in the last quarter.
Average portfolio weight of all funds dedicated to GRTS is 0.21%,
an increase
of 51.17%.
Total shares owned by institutions increased
in the last three months by 30.52% to 44,896K shares.
The put/call ratio of GRTS is 0.04, indicating a
bullish
outlook.
Gritstone Bio Background Information
(This description is provided by the company.)
Gritstone Oncology, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars-first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an ‘off-the-shelf’ shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
